作者:Olivier Corminboeuf、Guillaume Dunet、Mehdi Hafsi、Julien Grimont、Corinna Grisostomi、Solange Meyer、Christoph Binkert、Daniel Bur、Andrew Jones、Lars Prade、Reto Brun、Christoph Boss
DOI:10.1016/j.bmcl.2006.09.027
日期:2006.12
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results, targeting Plasmepsin II, a Plasmodium faleiparum aspartic protease active in hemoglobin degradation, a parasite specific catabolic pathway. The results show that the new structural class is not only inhibiting PMII in vitro but is also active in a P. falciparum infected human red blood cell assay. (c) 2006 Elsevier Ltd. All rights reserved.